Welcome: Guest | Site Use Options | Register | Login |

Vaccinex Inc

Vaccinex Inc

Profile last edited on: 12/16/2020
1895 Mount Hope Avenue
Rochester, NY 14620
  (585) 271-2700
Business Identifier: Novel therapeutic antibodies for neurodegenerative disorders and oncology
Public Profile:
With original ties to the University of Rochester, Vaccinex, Inc. (NASDAQ: VCNX) is taking a differentiated approach to treating neurodegenerative disease through the inhibition of semaphorin 4D (SEMA4D), a key driver of neuroinflammation. Actively involved in SBIR In the years following founding of the firm but not recently, the companys lead drug candidate, pepinemab, blocks SEMA4D and has potential as a disease-modifying treatment for Huntingtons, Alzheimers and other neurodegenerative diseases. Beyond neurology, Vaccinex has determined that, in combination with checkpoint inhibitors, pepinemab has potential to increase objective responses in oncology. The company additionally intends to leverage its proprietary drug discovery platform, ActivMAb, to create opportunities for future pipeline expansion and strategic collaborations.

 Synopsis: Awardee Business Condition
Year Founded First SBIR Year Date of Last Award
Employee Range VC funded? IP Holdings
Revenue Range Private/Public Exchange/Symbol :

Unlock access

To unlock access to all SBIR-STTR company Profiles, a FREE site registration is required. Click here to register or login if you already have an account

Smart Office Options

SBIR firms in the news


Is this YOUR Company?

Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached

Do you know about this Awardees?

Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Contact information

Innovation Development Institute, LLC

   45 Beach Bluff Avenue, Suite 300
     Swampscott,  MA 01907-1542

  Tel:  (781) 595-2920